Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Peptic Ulcer

  Free Subscription

Articles published in Helicobacter

Retrieve available abstracts of 151 articles:
HTML format

Single Articles

    December 2022
  1. ROKKAS T, Ekmektzoglou K, Graham DY
    Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis.
    Helicobacter. 2022 Dec 1:e12936. doi: 10.1111/hel.12936.
    PubMed     Abstract available

  2. LU L, Wang Y, Ye J, Han Y, et al
    Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Helicobacter. 2022 Dec 1:e12940. doi: 10.1111/hel.12940.
    PubMed     Abstract available

    November 2022
  3. YANG H, Mou Y, Hu B
    Discussion on the common controversies of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 27:e12938. doi: 10.1111/hel.12938.
    PubMed     Abstract available

  4. JI YH, Shi YM, Hei QW, Sun JM, et al
    Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 21:e12937. doi: 10.1111/hel.12937.
    PubMed     Abstract available

  5. TIAN XL, Suo BJ, Zhang H, Lu HP, et al
    Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Helicobacter. 2022 Nov 14:e12935. doi: 10.1111/hel.12935.
    PubMed     Abstract available

    October 2022
  6. HARA D, Okamura T, Iwaya Y, Nagaya T, et al
    Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development.
    Helicobacter. 2022 Oct 20:e12934. doi: 10.1111/hel.12934.
    PubMed     Abstract available

  7. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
    Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid.
    Helicobacter. 2022 Oct 20:e12933. doi: 10.1111/hel.12933.
    PubMed     Abstract available

    September 2022
  8. CHUAH YY, Wu DC, Chuah SK, Chen KY, et al
    REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020.
    Helicobacter. 2022 Sep 25:e12931. doi: 10.1111/hel.12931.
    PubMed     Abstract available

  9. HAN Z, Li Y, Kong Q, Liu J, et al
    Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
    Helicobacter. 2022 Sep 25:e12930. doi: 10.1111/hel.12930.
    PubMed     Abstract available

  10. ZHANG Y, Li X, Shan B, Zhang H, et al
    Perspectives from recent advances of Helicobacter pylori vaccines research.
    Helicobacter. 2022 Sep 22:e12926. doi: 10.1111/hel.12926.
    PubMed     Abstract available

  11. AZRAD M, Vazana D, On A, Paritski M, et al
    Antibiotic resistance patterns of Helicobacter pylori in North Israel - A six-year study.
    Helicobacter. 2022 Sep 15:e12932. doi: 10.1111/hel.12932.
    PubMed     Abstract available

  12. CHOI S, Kim N, Park JH, Nam RH, et al
    Effect of Helicobacter pylori infection and its eradication on the expression of tight junction proteins in the gastric epithelium in relation to gastric carcinogenesis.
    Helicobacter. 2022 Sep 5:e12929. doi: 10.1111/hel.12929.
    PubMed     Abstract available

    August 2022
  13. ARJMANDI D, Abdollahi A, Ardekani A, Razavian I, et al
    Helicobacter pylori infection and risk of multiple sclerosis: An updated meta-analysis.
    Helicobacter. 2022 Aug 31:e12927. doi: 10.1111/hel.12927.
    PubMed     Abstract available

  14. WERNLY S, Semmler G, Volkerer A, Flamm M, et al
    Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?
    Helicobacter. 2022 Aug 31:e12928. doi: 10.1111/hel.12928.
    PubMed     Abstract available

  15. SHI Y, Zheng H, Guo Z, Deng R, et al
    Effect of Helicobacter pylori on immunotherapy is gaining more attention.
    Helicobacter. 2022 Aug 29:e12925. doi: 10.1111/hel.12925.
    PubMed     Abstract available

  16. HU Y, Xu X, Ouyang YB, He C, et al
    Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2022 Aug 29:e12923. doi: 10.1111/hel.12923.
    PubMed     Abstract available

  17. BORDIN D, Morozov S, Plavnik R, Bakulina N, et al
    Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial.
    Helicobacter. 2022 Aug 16:e12924. doi: 10.1111/hel.12924.
    PubMed     Abstract available

  18. TANAKA I, Ono S, Watanabe Y, Yamamoto H, et al
    Long-term changes in aberrant DNA methylation and gastritis after Helicobacter pylori eradication focused on metachronous gastric cancer.
    Helicobacter. 2022 Aug 8:e12915. doi: 10.1111/hel.12915.
    PubMed     Abstract available

  19. HAN YY, Long H, Lin Y, He Q, et al
    Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study.
    Helicobacter. 2022 Aug 8. doi: 10.1111/hel.12922.
    PubMed     Abstract available

  20. SHAO Y, Lin Y, Wang B, Miao M, et al
    Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
    Helicobacter. 2022 Aug 8:e12920. doi: 10.1111/hel.12920.
    PubMed     Abstract available

  21. ZHONG Z, Zhan B, Xu B, Gao H, et al
    Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization.
    Helicobacter. 2022 Aug 8:e12916. doi: 10.1111/hel.12916.

  22. INAMASU Y, Ogawa M, Saito M, Harada M, et al
    Helicobacter pylori results in lysis and death after exposure to water.
    Helicobacter. 2022 Aug 8:e12921. doi: 10.1111/hel.12921.
    PubMed     Abstract available

    July 2022
  23. MUNIR M, LeMaitre B, Lobo Z, Psevdos G, et al
    A 15-year review of Helicobacter pylori screening and treatment among United States Veterans.
    Helicobacter. 2022 Jul 28:e12919. doi: 10.1111/hel.12919.

  24. MOMMERSTEEG MC, Yu BT, van den Bosch TPP, von der Thusen JH, et al
    Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation.
    Helicobacter. 2022 Jul 28:e12917. doi: 10.1111/hel.12917.
    PubMed     Abstract available

  25. GAO W, Teng G, Wang C, Xu Y, et al
    Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study i
    Helicobacter. 2022 Jul 25:e12918. doi: 10.1111/hel.12918.
    PubMed     Abstract available

  26. CHEN MJ, Bair MJ, Chen PY, Lee JY, et al
    Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis.
    Helicobacter. 2022 Jul 18:e12914. doi: 10.1111/hel.12914.
    PubMed     Abstract available

  27. SUKRI A, Hanafiah A, Kosai NR, Mohammed Taher M, et al
    New insight on the role of Helicobacter pylori cagA in the expression of cell surface antigens with important biological functions in gastric carcinogenesis.
    Helicobacter. 2022 Jul 18:e12913. doi: 10.1111/hel.12913.
    PubMed     Abstract available

  28. KONG Q, Li Y, Li R, Li Z, et al
    Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study.
    Helicobacter. 2022 Jul 11:e12912. doi: 10.1111/hel.12912.
    PubMed     Abstract available

    June 2022
  29. MA J, Yu M, Shao QQ, Yu XC, et al
    Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
    Helicobacter. 2022 Jun 15:e12911. doi: 10.1111/hel.12911.
    PubMed     Abstract available

  30. SOUISSI S, Makni C, Belhadj Ammar L, Bousnina O, et al
    Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study.
    Helicobacter. 2022 Jun 13:e12910. doi: 10.1111/hel.12910.
    PubMed     Abstract available

  31. XIAO W, Ma ZS
    Influences of Helicobacter pylori infection on diversity, heterogeneity, and composition of human gastric microbiomes across stages of gastric cancer development.
    Helicobacter. 2022 Jun 9:e12899. doi: 10.1111/hel.12899.
    PubMed     Abstract available

    May 2022
  32. INOKUCHI K, Mori H, Matsuzaki J, Hirata K, et al
    Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Helicobacter. 2022 May 29:e12900. doi: 10.1111/hel.12900.
    PubMed     Abstract available

  33. AKAR M, Saticioglu IB, Karakaya E, Kayman T, et al
    Two novel sequence types of Helicobacter pylori strains: The first report from Turkey.
    Helicobacter. 2022 May 23:e12907. doi: 10.1111/hel.12907.

  34. HE C, Peng C, Xu X, Li N, et al
    Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota.
    Helicobacter. 2022 May 9:e12898. doi: 10.1111/hel.12898.
    PubMed     Abstract available

  35. PHUNG HTT, Deenonpoe R, Suttiprapa S, Mairiang E, et al
    Persistent advanced periductal fibrosis is associated with cagA-positive Helicobacter pylori infection in post-praziquantel treatment of opisthorchiasis.
    Helicobacter. 2022 May 9:e12897. doi: 10.1111/hel.12897.
    PubMed     Abstract available

    April 2022
  36. SAIF N, Jensen N, Farrar E, Blackstone S, et al
    Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States.
    Helicobacter. 2022 Apr 28:e12894. doi: 10.1111/hel.12894.
    PubMed     Abstract available

  37. HU Y, Xu X, Ouyang YB, He C, et al
    Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
    Helicobacter. 2022 Apr 25:e12896. doi: 10.1111/hel.12896.
    PubMed     Abstract available

  38. LI C, Lu C, Gong L, Liu J, et al
    SHP2/SPI1axis promotes glycolysis and the inflammatory response of macrophages in Helicobacter pylori-induced pediatric gastritis.
    Helicobacter. 2022 Apr 19:e12895. doi: 10.1111/hel.12895.
    PubMed     Abstract available

  39. JIANG F, Guo CG, Cheung KS, Li B, et al
    Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study.
    Helicobacter. 2022 Apr 12:e12893. doi: 10.1111/hel.12893.
    PubMed     Abstract available

  40. CHUA BQY, Chong VWS, Teng TZJ, Chia CTW, et al
    Does technology-enhanced communication improve Helicobacter pylori eradication outcomes?-A meta-analysis.
    Helicobacter. 2022 Apr 1:e12890. doi: 10.1111/hel.12890.
    PubMed     Abstract available

  41. SONG Z, Chen Y, Lu H, Zeng Z, et al
    Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study.
    Helicobacter. 2022 Apr 1:e12889. doi: 10.1111/hel.12889.
    PubMed     Abstract available

    March 2022
  42. KOWADA A, Asaka M
    Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
    Helicobacter. 2022 Mar 27:e12886. doi: 10.1111/hel.12886.
    PubMed     Abstract available

  43. HSIEH H, Yang HB, Sheu BS, Yang YJ, et al
    Atrophic gastritis in Helicobacter pylori-infected children.
    Helicobacter. 2022 Mar 20:e12885. doi: 10.1111/hel.12885.
    PubMed     Abstract available

  44. POLIVANOVA TV, Malaty H, Vshivkov VA
    Epidemiology Helicobacter pylori infection in children in the Tyva Republic (Russia).
    Helicobacter. 2022 Mar 13:e12882. doi: 10.1111/hel.12882.
    PubMed     Abstract available

  45. KOUNTOURAS J, Kazakos E, Polyzos SA, Chatzopoulos D, et al
    GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Mar 7:e12884. doi: 10.1111/hel.12884.

  46. YOKOTA K, Osaki T, Hayashi S, Yokota SI, et al
    Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.
    Helicobacter. 2022 Mar 7:e12874. doi: 10.1111/hel.12874.
    PubMed     Abstract available

  47. MORAIS S, Costa A, Albuquerque G, Araujo N, et al
    "True" Helicobacter pylori infection and non-cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project.
    Helicobacter. 2022 Mar 2:e12883. doi: 10.1111/hel.12883.
    PubMed     Abstract available

    February 2022
  48. EL HAFA F, Wang T, Ndifor VM, Jin G, et al
    Association between Helicobacter pylori antibodies determined by multiplex serology and gastric cancer risk: A meta-analysis.
    Helicobacter. 2022 Feb 24:e12881. doi: 10.1111/hel.12881.
    PubMed     Abstract available

  49. ZHOU BG, Yan XL, Wan LY, Zhang Q, et al
    Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2022 Feb 18:e12869. doi: 10.1111/hel.12869.
    PubMed     Abstract available

  50. LI H, Shen Y, Song X, Tang X, et al
    Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing.
    Helicobacter. 2022 Feb 12:e12873. doi: 10.1111/hel.12873.
    PubMed     Abstract available

  51. ZHA J, Li YY, Qu JY, Yang XX, et al
    Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.
    Helicobacter. 2022 Feb 12:e12880. doi: 10.1111/hel.12880.
    PubMed     Abstract available

  52. SHAO QQ, Yu XC, Yu M, Ma J, et al
    Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Helicobacter. 2022 Feb 12:e12876. doi: 10.1111/hel.12876.
    PubMed     Abstract available

  53. LI Y, Huang Z, Shang Y, Xie X, et al
    Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China.
    Helicobacter. 2022 Feb 6:e12879. doi: 10.1111/hel.12879.
    PubMed     Abstract available

  54. SHI Y, Zheng H, Wang M, Ding S, et al
    Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
    Helicobacter. 2022 Feb 3:e12878. doi: 10.1111/hel.12878.
    PubMed     Abstract available

    January 2022
  55. QIANG L, Hu J, Tian M, Li Y, et al
    Extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis.
    Helicobacter. 2022 Jan 31:e12877. doi: 10.1111/hel.12877.
    PubMed     Abstract available

  56. VAILLANT L, Oster P, McMillan B, Orozco Fernandez E, et al
    GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Jan 29:e12875. doi: 10.1111/hel.12875.
    PubMed     Abstract available

  57. DI MARIO F, Crafa P, Barchi A, Franzoni L, et al
    Pepsinogen II in gastritis and Helicobacter pylori infection.
    Helicobacter. 2022 Jan 8:e12872. doi: 10.1111/hel.12872.
    PubMed     Abstract available

  58. XU C, Wu Y, Xu S
    Association between Helicobacter pylori infection and growth outcomes in children: A meta-analysis.
    Helicobacter. 2022 Jan 8:e12861. doi: 10.1111/hel.12861.
    PubMed     Abstract available

  59. CIFUENTES SG, Prado MB, Fornasini M, Cohen H, et al
    Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy.
    Helicobacter. 2022 Jan 6:e12870. doi: 10.1111/hel.12870.
    PubMed     Abstract available

    December 2021
  60. WANG L, Yao H, Tong T, Lau K, et al
    Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies.
    Helicobacter. 2021 Dec 30:e12871. doi: 10.1111/hel.12871.
    PubMed     Abstract available

  61. HUANG JG, Lim SYS, Aw MM, Quak SH, et al
    Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort.
    Helicobacter. 2021 Dec 27:e12868. doi: 10.1111/hel.12868.
    PubMed     Abstract available

    November 2021
  62. SHI H, Li Y, Dong C, Si G, et al
    Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta-analysis.
    Helicobacter. 2021 Nov 28:e12865. doi: 10.1111/hel.12865.
    PubMed     Abstract available

  63. FERREIRA EO, Lagace-Wiens P, Klein J
    Campylobacter concisus gastritis masquerading as Helicobacter pylori on gastric biopsy.
    Helicobacter. 2021 Nov 24:e12864. doi: 10.1111/hel.12864.
    PubMed     Abstract available

  64. MURATA M, Sugimoto M, Miyamoto S, Kawai T, et al
    Long-term improvement in constipation-related symptoms after Helicobacter pylori eradication therapy.
    Helicobacter. 2021 Nov 17:e12863. doi: 10.1111/hel.12863.
    PubMed     Abstract available

  65. ZAGARI RM, Romano M, Frazzoni L, Marasco G, et al
    Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
    Helicobacter. 2021 Nov 11:e12862. doi: 10.1111/hel.12862.
    PubMed     Abstract available

    October 2021
  66. YU J, Yang P, Qin X, Li C, et al
    Impact of smoking on the eradication of Helicobacter pylori.
    Helicobacter. 2021 Oct 27:e12860. doi: 10.1111/hel.12860.
    PubMed     Abstract available

  67. CHEN MJ, Chen CC, Huang YC, Tseng CC, et al
    The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial.
    Helicobacter. 2021 Oct 27:e12857. doi: 10.1111/hel.12857.
    PubMed     Abstract available

  68. YANG C, Liang L, Lv P, Liu L, et al
    Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
    Helicobacter. 2021 Oct 10:e12856. doi: 10.1111/hel.12856.
    PubMed     Abstract available

  69. BENEJAT L, Ducournau A, Domingues-Martins C, Lecoeur M, et al
    Adaptation of an in-house PCR for the detection of Helicobacter pylori and the mutations associated with macrolide resistance into ready-to-use PCR microwell strips.
    Helicobacter. 2021 Oct 10:e12855. doi: 10.1111/hel.12855.
    PubMed     Abstract available

  70. LAPIDOT Y, Reshef L, Cohen D, Muhsen K, et al
    Helicobacter pylori and the intestinal microbiome among healthy school-age children.
    Helicobacter. 2021 Oct 7:e12854. doi: 10.1111/hel.12854.
    PubMed     Abstract available

    September 2021
  71. VARMA M, Yoe J
    Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia.
    Helicobacter. 2021 Sep 22:e12850. doi: 10.1111/hel.12850.

  72. LUCERO Y, Lagomarcino AJ, Torres JP, Roessler P, et al
    Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
    Helicobacter. 2021 Sep 15:e12853. doi: 10.1111/hel.12853.
    PubMed     Abstract available

  73. ZHAO H, Yan P, Zhang N, Feng L, et al
    The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis.
    Helicobacter. 2021 Sep 12:e12852. doi: 10.1111/hel.12852.
    PubMed     Abstract available

  74. CHEN HY, Hu Y, Xu XB, Zhou YA, et al
    Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
    Helicobacter. 2021 Sep 7:e12849. doi: 10.1111/hel.12849.
    PubMed     Abstract available

  75. SUZUKI S, Gotoda T, Takano C, Horii T, et al
    Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
    Helicobacter. 2021 Sep 6:e12851. doi: 10.1111/hel.12851.
    PubMed     Abstract available

    August 2021
  76. YUAN Z, Xiao S, Li S, Suo B, et al
    The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults.
    Helicobacter. 2021 Aug 26:e12848. doi: 10.1111/hel.12848.
    PubMed     Abstract available

  77. YAO X, Xiao S, Zhou L
    Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
    Helicobacter. 2021 Aug 20:e12846. doi: 10.1111/hel.12846.
    PubMed     Abstract available

  78. LEE JW, Kim N, Nam RH, Jang JY, et al
    Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
    Helicobacter. 2021 Aug 12:e12844. doi: 10.1111/hel.12844.
    PubMed     Abstract available

  79. HSU PI, Tsay FW, Kao JY, Peng NJ, et al
    Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
    Helicobacter. 2021 Aug 12:e12840. doi: 10.1111/hel.12840.
    PubMed     Abstract available

  80. GUO R, Wu S, Guan L, Xie Y, et al
    Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients.
    Helicobacter. 2021 Aug 11:e12843. doi: 10.1111/hel.12843.
    PubMed     Abstract available

    July 2021
  81. GONG L, El-Omar EM
    Application of molecular techniques in Helicobacter pylori detection: limitations and improvements.
    Helicobacter. 2021 Jul 31:e12841. doi: 10.1111/hel.12841.

  82. OUYANG Y, Zhang W, Huang Y, Wang Y, et al
    Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 31:e12838. doi: 10.1111/hel.12838.
    PubMed     Abstract available

  83. LI N, Xu X, Yang H, Wang H, et al
    Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
    Helicobacter. 2021 Jul 30:e12842. doi: 10.1111/hel.12842.
    PubMed     Abstract available

  84. ZHAO J, Zou Y, Li K, Huang X, et al
    Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 28:e12839. doi: 10.1111/hel.12839.
    PubMed     Abstract available

  85. ZOU PY, Hu J, Zhao JT, Zhao Z, et al
    10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis.
    Helicobacter. 2021 Jul 28:e12833. doi: 10.1111/hel.12833.
    PubMed     Abstract available

  86. KOWADA A, Asaka M
    Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Helicobacter. 2021 Jul 18:e12837. doi: 10.1111/hel.12837.
    PubMed     Abstract available

  87. GUNATHILAKE M, Lee J, Choi IJ, Kim YI, et al
    Association between bacteria other than Helicobacter pylori and the risk of gastric cancer.
    Helicobacter. 2021 Jul 15:e12836. doi: 10.1111/hel.12836.
    PubMed     Abstract available

  88. OUYANG Y, Zhu Z, Huang L, Zeng C, et al
    Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
    Helicobacter. 2021 Jul 13:e12835. doi: 10.1111/hel.12835.
    PubMed     Abstract available

  89. GUNARATNE AW, Hamblin H, Clancy A, Magat AJMC, et al
    Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
    Helicobacter. 2021 Jul 10:e12830. doi: 10.1111/hel.12830.
    PubMed     Abstract available

    cagA+ Helicobacter pylori infection and N-nitrosodimethylamine and cholangiocarcinoma.
    Helicobacter. 2021 Jul 8:e12834. doi: 10.1111/hel.12834.

  91. MA H, Zhao XH, Zhang LL, Wu LM, et al
    Application of WeChat platform in the management of patients infected with Helicobacter pylori.
    Helicobacter. 2021 Jul 7:e12832. doi: 10.1111/hel.12832.
    PubMed     Abstract available

  92. HE Y, Ning J, Li B, Guo H, et al
    IL-9 contributes to the host immune response against Helicobacter pylori and helps limit infection in a Mouse Model.
    Helicobacter. 2021 Jul 7:e12827. doi: 10.1111/hel.12827.
    PubMed     Abstract available

    June 2021
  93. TSAI CF, Chen MH, Wang YP, Liu PY, et al
    Increased risk of short-term depressive disorder after Helicobacter pylori eradication: A population-based nested cohort study.
    Helicobacter. 2021 Jun 11:e12824. doi: 10.1111/hel.12824.
    PubMed     Abstract available

  94. QIU E, Jin S, Xiao Z, Chen Q, et al
    CRISPR-based detection of Helicobacter pylori in stool samples.
    Helicobacter. 2021 Jun 11:e12828. doi: 10.1111/hel.12828.
    PubMed     Abstract available

  95. KOTILEA K, Cadranel S, Salame A, Nguyen J, et al
    Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
    Helicobacter. 2021 Jun 7:e12825. doi: 10.1111/hel.12825.
    PubMed     Abstract available

    May 2021
  96. MONZANI A, Lionetti P, Rabbone I, Lionetti E, et al
    The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?
    Helicobacter. 2021 May 28:e12826. doi: 10.1111/hel.12826.

  97. DANGTAKOT R, Intuyod K, Chamgramol Y, Pairojkul C, et al
    CagA(+) Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
    Helicobacter. 2021 May 24:e12817. doi: 10.1111/hel.12817.
    PubMed     Abstract available

  98. LI C, Shi Y, Suo B, Tian X, et al
    PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
    Helicobacter. 2021 May 17:e12816. doi: 10.1111/hel.12816.
    PubMed     Abstract available

  99. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report.
    Helicobacter. 2021 May 11:e12814. doi: 10.1111/hel.12814.
    PubMed     Abstract available

  100. ZHANG Z, Chen S, Fan M, Ruan G, et al
    Helicobacter pylori induces gastric cancer via down-regulating miR-375 to inhibit dendritic cell maturation.
    Helicobacter. 2021 May 3:e12813. doi: 10.1111/hel.12813.
    PubMed     Abstract available

    April 2021
  101. HERNANDEZ C, Toledo-Stuardo K, Garcia-Gonzalez P, Garrido-Tapia M, et al
    Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Helicobacter. 2021 Apr 29:e12812. doi: 10.1111/hel.12812.
    PubMed     Abstract available

  102. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan.
    Helicobacter. 2021 Apr 27:e12811. doi: 10.1111/hel.12811.
    PubMed     Abstract available

  103. WANG X, Shu X, Li Q, Li Y, et al
    Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.
    Helicobacter. 2021 Apr 27:e12810. doi: 10.1111/hel.12810.
    PubMed     Abstract available

  104. ZHOU Y, Ye Z, Wang Y, Huang Z, et al
    Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
    Helicobacter. 2021 Apr 25:e12809. doi: 10.1111/hel.12809.
    PubMed     Abstract available

  105. LI SY, Li J, Dong XH, Teng GG, et al
    The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
    Helicobacter. 2021 Apr 16:e12804. doi: 10.1111/hel.12804.
    PubMed     Abstract available

  106. XIE W, Zhao W, Zou Z, Kong L, et al
    Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.
    Helicobacter. 2021 Apr 12:e12807. doi: 10.1111/hel.12807.
    PubMed     Abstract available

  107. DO AD, Chang CC, Su CH, Hsu YM, et al
    Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions.
    Helicobacter. 2021 Apr 11:e12806. doi: 10.1111/hel.12806.
    PubMed     Abstract available

  108. TURNER KO, Lindberg GM, Genta RM
    Gastric granulomas and Helicobacter pylori: An incidental relationship.
    Helicobacter. 2021 Apr 11:e12805. doi: 10.1111/hel.12805.
    PubMed     Abstract available

  109. YORGUC E, Gulerman HF, Kalkan IH, Guven B, et al
    Comparison of clinical outcomes and FOXP3, IL-17A responses in Helicobacter pylori infection in children versus adults.
    Helicobacter. 2021 Apr 5:e12795. doi: 10.1111/hel.12795.
    PubMed     Abstract available

  110. KUBOTA-AIZAWA S, Matsubara Y, Kanemoto H, Mimuro H, et al
    Transmission of Helicobacter pylori between a human and two dogs: A case report.
    Helicobacter. 2021 Apr 5:e12798. doi: 10.1111/hel.12798.
    PubMed     Abstract available

    March 2021
  111. LI Y, Li X, Tan Z
    An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis.
    Helicobacter. 2021 Mar 25:e12799. doi: 10.1111/hel.12799.
    PubMed     Abstract available

  112. CHIANG TH, Chen CC, Tseng PH, Liou JM, et al
    Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
    Helicobacter. 2021 Mar 19:e12801. doi: 10.1111/hel.12801.
    PubMed     Abstract available

  113. HEFFLEY JD, Zubarik R
    A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease.
    Helicobacter. 2021 Mar 15:e12800. doi: 10.1111/hel.12800.
    PubMed     Abstract available

  114. MARUBASHI K, Takakusagi S, Yokoyama Y, Kizawa K, et al
    Changes of (18) F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach.
    Helicobacter. 2021 Mar 8:e12797. doi: 10.1111/hel.12797.
    PubMed     Abstract available

  115. ZHAO JB, Yuan L, Yu XC, Shao QQ, et al
    Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis.
    Helicobacter. 2021 Mar 6:e12793. doi: 10.1111/hel.12793.
    PubMed     Abstract available

  116. JAIN U, Saxena K, Chauhan N
    Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection.
    Helicobacter. 2021 Mar 5:e12796. doi: 10.1111/hel.12796.
    PubMed     Abstract available

  117. TENG TZJ, Sudharsan M, Yau JWK, Tan W, et al
    Helicobacter pylori knowledge and perception among multi-ethnic Asians.
    Helicobacter. 2021 Mar 3:e12794. doi: 10.1111/hel.12794.
    PubMed     Abstract available

  118. KIM YJ, Chung WC, Kim DB
    Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
    Helicobacter. 2021 Mar 1:e12792. doi: 10.1111/hel.12792.
    PubMed     Abstract available

    February 2021
  119. HUANG Y, Ding Y, Xu H, Shen C, et al
    Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
    Helicobacter. 2021 Feb 20:e12785. doi: 10.1111/hel.12785.
    PubMed     Abstract available

  120. XIE M, Li Q, Zhang B, Zhang Q, et al
    Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
    Helicobacter. 2021 Feb 18:e12791. doi: 10.1111/hel.12791.
    PubMed     Abstract available

  121. GANTUYA B, El Serag HB, Saruuljavkhlan B, Azzaya D, et al
    Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis.
    Helicobacter. 2021 Feb 17:e12790. doi: 10.1111/hel.12790.
    PubMed     Abstract available

  122. LEE BE, Kim JS, Kim BW, Kim JH, et al
    Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years.
    Helicobacter. 2021 Feb 17:e12780. doi: 10.1111/hel.12780.
    PubMed     Abstract available

  123. WU ZF, Zou K, Xiang CJ, Jin ZJ, et al
    Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa.
    Helicobacter. 2021 Feb 17:e12786. doi: 10.1111/hel.12786.
    PubMed     Abstract available

  124. YANG KY, Kao CY, Su MS, Wang S, et al
    Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori.
    Helicobacter. 2021 Feb 15:e12787. doi: 10.1111/hel.12787.
    PubMed     Abstract available

  125. LACOUT C, Savey L, Bourguiba R, Giurgea I, et al
    "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france".
    Helicobacter. 2021 Feb 15:e12789. doi: 10.1111/hel.12789.
    PubMed     Abstract available

  126. ETO H, Suzuki S, Kusano C, Ikehara H, et al
    Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Helicobacter. 2021 Feb 12:e12788. doi: 10.1111/hel.12788.
    PubMed     Abstract available

  127. HU Y, Ouyang Y, Zhu Y, Lu NH, et al
    Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2021 Feb 3:e12784. doi: 10.1111/hel.12784.
    PubMed     Abstract available

    January 2021
  128. PARK Y, Kim TJ, Lee H, Yoo H, et al
    Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study.
    Helicobacter. 2021 Jan 28:e12783. doi: 10.1111/hel.12783.
    PubMed     Abstract available

  129. DOMANOVICH-ASOR T, Craddock HA, Motro Y, Khalfin B, et al
    Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny.
    Helicobacter. 2021 Jan 25:e12782. doi: 10.1111/hel.12782.
    PubMed     Abstract available

  130. SONG X, Cai C, Jin Q, Chen X, et al
    The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis.
    Helicobacter. 2021 Jan 19:e12781. doi: 10.1111/hel.12781.
    PubMed     Abstract available

  131. WEN Y, Huang H, Tang T, Yang H, et al
    AI-2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori-induced inflammatory response of gastric epithelial cells.
    Helicobacter. 2021 Jan 5:e12778. doi: 10.1111/hel.12778.
    PubMed     Abstract available

  132. MUNOZ AB, Trespalacios-Rangel AA, Vale FF
    An American lineage of Helicobacter pylori prophages found in Colombia.
    Helicobacter. 2021 Jan 5:e12779. doi: 10.1111/hel.12779.
    PubMed     Abstract available

  133. JUNG K, Kim DH, Seo HI, Gong EJ, et al
    Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis.
    Helicobacter. 2021 Jan 5:e12774. doi: 10.1111/hel.12774.
    PubMed     Abstract available

    December 2020
  134. XUE Q, Li X, Li Y, Xu J, et al
    Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis.
    Helicobacter. 2020 Dec 23:e12771. doi: 10.1111/hel.12771.
    PubMed     Abstract available

  135. QARIA MA, Qumar S, Sepe LP, Ahmed N, et al
    Cholesterol glucosylation-based survival strategy in Helicobacter pylori.
    Helicobacter. 2020 Dec 23:e12777. doi: 10.1111/hel.12777.
    PubMed     Abstract available

  136. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
    Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
    Helicobacter. 2020 Dec 23:e12776. doi: 10.1111/hel.12776.
    PubMed     Abstract available

  137. JUKIC I, Vukovic J, Rusic D, Bozic J, et al
    Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
    Helicobacter. 2020 Dec 23:e12775. doi: 10.1111/hel.12775.
    PubMed     Abstract available

  138. BANGA NDZOUBOUKOU JL, Lei Q, Ullah N, Zhang Y, et al
    Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Helicobacter. 2020 Dec 1:e12758. doi: 10.1111/hel.12758.
    PubMed     Abstract available

    November 2020
  139. CEN Q, Gao T, Ren Y, Lu X, et al
    Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice.
    Helicobacter. 2020 Nov 20:e12772. doi: 10.1111/hel.12772.
    PubMed     Abstract available

  140. GRAHAM DY, Megraud F
    Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy.
    Helicobacter. 2020 Nov 18:e12773. doi: 10.1111/hel.12773.

  141. SINGH H, Chung H, Awan I, Mone A, et al
    Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.
    Helicobacter. 2020 Nov 9:e12769. doi: 10.1111/hel.12769.
    PubMed     Abstract available

    October 2020
  142. PIH GY, Choi KD, Gong EJ, Na HK, et al
    Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
    Helicobacter. 2020 Oct 28:e12759. doi: 10.1111/hel.12759.
    PubMed     Abstract available

  143. MEGRAUD F, Alix C, Charron P, Benejat L, et al
    Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
    Helicobacter. 2020 Oct 22:e12767. doi: 10.1111/hel.12767.
    PubMed     Abstract available

  144. KE H, Li J, Lu B, Yang C, et al
    The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
    Helicobacter. 2020 Oct 21:e12768. doi: 10.1111/hel.12768.
    PubMed     Abstract available

  145. QUMAR S, Nguyen TH, Nahar S, Sarker N, et al
    A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.
    Helicobacter. 2020 Oct 18:e12766. doi: 10.1111/hel.12766.
    PubMed     Abstract available

  146. MIYATA E, Kudo T, Ikuse T, Tokita K, et al
    Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years.
    Helicobacter. 2020 Oct 18:e12764. doi: 10.1111/hel.12764.
    PubMed     Abstract available

  147. HOFREUTER D, Behrendt J, Franz A, Meyer J, et al
    Antimicrobial resistance of Helicobacter pylori in an eastern German region.
    Helicobacter. 2020 Oct 17:e12765. doi: 10.1111/hel.12765.
    PubMed     Abstract available

  148. SONG Z, Zhou L, Xue Y, Suo B, et al
    A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Helicobacter. 2020 Oct 11:e12762. doi: 10.1111/hel.12762.
    PubMed     Abstract available

  149. WANG B, Yu M, Zhang R, Chen S, et al
    A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease.
    Helicobacter. 2020 Oct 7:e12761. doi: 10.1111/hel.12761.
    PubMed     Abstract available

  150. ALVAREZ CS, Florio AA, Butt J, Rivera-Andrade A, et al
    Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.
    Helicobacter. 2020 Oct 2:e12756. doi: 10.1111/hel.12756.
    PubMed     Abstract available

  151. HUANG JW, Xie C, Niu Z, He LJ, et al
    The relation between Helicobacter pylori immunoglobulin G seropositivity and leukocyte telomere length in US adults from NHANES 1999-2000.
    Helicobacter. 2020 Oct 1:e12760. doi: 10.1111/hel.12760.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.